An overview on the implementation of HPV vaccination in Europe

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 128-135

  Bonanni, Paolo ^a   Levi, Miriam ^a   Latham, Nina B ^b   Bechini, Angela ^a   Tiscione, Emilia ^a   Lai, Piero ^c   Panatto, Donatella ^c   Gasparini, Roberto ^c   Boccalini, Sara ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SANOFI PASTEUR   (France)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cervical cancer; Communication; Europe; HPV vaccination; Vaccination programs

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; DRUG SAFETY; EUROPE; HEALTH CARE PLANNING; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; PRECANCER; REVIEW; STRATEGIC PLANNING; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

EUROPE; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 80755152170     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14575     Document Type: Review

References (43)

1. EFPIA 1999-2002.
2. Lattanzi M, Rappuoli R. Vaccination: past, present and future. In: Grandi G, Ed. Genomics, Proteomics and Vaccines: John Wiley and Sons Ltd 2004; 3-22.
3. Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80:3812-5. (Pubitemid 13063146)
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9. (Pubitemid 29406813)
5. Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer: a populationbased case-control study in Colombia and Spain. Int J Cancer 1992; 52:743-9.
6. La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine 2010; 28:3379-84.
7. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765-81.
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010.
9. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006; 30:1513-8. (Pubitemid 44808787)
10. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204. (Pubitemid 40450709)
11. Cupp MR, Malek RS, Goellner JR, Espy MJ, Smith TF. Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology 1996; 48:551-5. (Pubitemid 26357418)
12. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944-56. (Pubitemid 46740304)
13. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345:1890-900. (Pubitemid 33716564)
14. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95:1772-83. (Pubitemid 38008900)
15. Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007; 8:420-9. (Pubitemid 46621770)
16. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121:621-32. (Pubitemid 46986496)
17. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical and molecular entity. Semin Oncol 2004; 31:744-54. (Pubitemid 39602680)
18. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75. (Pubitemid 40270113)
19. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35.
20. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11:781-9.
21. Licitra L, Zigon G, Gatta G, Sanchez MJ, Berrino F. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am 2008; 22:1143-53.
22. Lassen P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010; 95:371-80.
23. Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005; 32:59-66.
24. Goon PK, Stanley MA, Ebmeyer J, Steinsträsser L, Upile T, Jerjes W, et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009; 1.
25. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8. (Pubitemid 127695953)
26. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9. (Pubitemid 46843434)
27. Moscicki A, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, et al. Anamnestic response elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in young women. Paper presented at: Eurogin 2010 Congress Monte Carlo, Monaco 2010.
28. IARC. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Lyon: IARC Press 2005; 10:1-302.
29. Arblaster L, Lambert M, Entwistle V, Forster M, Fullerton D, Sheldon T, et al. A systematic review of the effectiveness of health service interventions aimed at reducing inequalities in health. J Health Serv Res Policy 1996; 1:93-103. (Pubitemid 26411149)
30. Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010; 28:4719-30.
31. Rivkind AI, Marshood M, Durst AL, Becker Y. Cianidanol ([+]-cyanidanol-3) prevents the development of abdominal adhesions in rats. Arch Surg 1983; 118:1431-3. (Pubitemid 14206194)
32. Noakes K, Yarwood J, Salisbury D. Parental response to the introduction of a vaccine against human papilloma virus. Hum Vaccin 2006; 2:243-8. (Pubitemid 46025655)
33. Aouba A, Péquignot F, Bovet M, Jougla E. Sudden infant death syndrome: situation in 2005 and trends since 1975. BEH thématique 2008; 3:18-21.
34. Hatton F, Bouvier-Colle MH, Blondel B, Pequignot F, Letoullec A. Trends in infant mortality in France: rates and causes of death from 1950 to 1997. Archives de Pédiatrie 2000; 7:489-500. (Pubitemid 30305482)
35. Messiah A, Flahault A. Absence de liaison entre la vaccination tetravalente et le syndrome de mort subite du nourrisson. Bulletin Épidémiologique Hebdomadaire 1986; 52:2.
36. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26:979-84. (Pubitemid 350287577)
37. Langmuir AD. The surveillance of communicable diseases of national importance. N Engl J Med 1963; 268:182-92.
38. ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill 2009; 14.
39. Fairley C, Hocking J, Gurrin L, Chen M, Donovan B, Bradshaw B. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
40. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009; 45:2632-9.
41. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626-36.
42. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62:870-8.
43. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001; 11:598-603.